Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 16-Sep-24 8:49 PM View:  | Lewicki John A. Chief Scientific Officer | Mereo Biopharma Group Plc (MREO) | 13-Sep-24 | Sale | 10,937 | $4.22 | $46,165.10 | (11%) 103.76K to 92.83K | |
| 16-Sep-24 8:46 PM View: | Hughes-Wilson Alexandra See Remarks | Mereo Biopharma Group Plc (MREO) | 13-Sep-24 | Sale | 100,312 | $4.22 | $423,417.00 | (67%) 150.79K to 50.48K | |
| 16-Sep-24 8:48 PM View: | Sermon Charles General Counsel | Mereo Biopharma Group Plc (MREO) | 13-Sep-24 | Sale | 20,946 | $4.22 | $88,413.10 | (9%) 240.01K to 219.06K | |
| 16-Sep-24 8:50 PM View: | Pollard-Knight Denise Chief Executive Officer Director | Mereo Biopharma Group Plc (MREO) | 13-Sep-24 | Sale | 60,046 | $4.22 | $253,454.00 | (7%) 868.97K to 808.92K | |
| 16-Sep-24 8:47 PM View: | Fox Chrisitne Ann Chief Financial Officer | Mereo Biopharma Group Plc (MREO) | 13-Sep-24 | Sale | 19,158 | $4.22 | $80,865.90 | (18%) 108.44K to 89.28K | |
| 16-Sep-24 8:49 PM View: | Lewicki John A. Chief Scientific Officer | Mereo Biopharma Group Plc (MREO) | 12-Sep-24 | Private Sale | 5,212 | $4.47 | $23,311.70 | (5%) 108.97K to 103.76K | |
| 16-Sep-24 8:46 PM View: | Hughes-Wilson Alexandra See Remarks | Mereo Biopharma Group Plc (MREO) | 12-Sep-24 | Private Sale | 47,798 | $4.47 | $213,786.00 | (24%) 198.59K to 150.79K | |
| 16-Sep-24 8:48 PM View: | Sermon Charles General Counsel | Mereo Biopharma Group Plc (MREO) | 12-Sep-24 | Private Sale | 9,980 | $4.47 | $44,637.50 | (4%) 249.99K to 240.01K | |
| 16-Sep-24 8:50 PM View: | Pollard-Knight Denise Chief Executive Officer Director | Mereo Biopharma Group Plc (MREO) | 12-Sep-24 | Private Sale | 28,611 | $4.47 | $127,968.00 | (3%) 897.58K to 868.97K | |
| 16-Sep-24 8:47 PM View: | Fox Chrisitne Ann Chief Financial Officer | Mereo Biopharma Group Plc (MREO) | 12-Sep-24 | Private Sale | 9,128 | $4.47 | $40,826.80 | (8%) 117.57K to 108.44K | |
| 13-Sep-24 4:47 PM View: | Hughes-Wilson Alexandra See Remarks | Mereo Biopharma Group Plc (MREO) | 11-Sep-24 | Option Exercise | 208,333 | $0.99 | $206,416.00 | 603% 34.55K to 242.88K | |
| 13-Sep-24 4:57 PM View: | Sermon Charles General Counsel | Mereo Biopharma Group Plc (MREO) | 11-Sep-24 | Option Exercise | 65,600 | -- | -- | 36% 184.39K to 249.99K | |
| 13-Sep-24 4:49 PM View: | Pollard-Knight Denise Chief Executive Officer Director | Mereo Biopharma Group Plc (MREO) | 11-Sep-24 | Option Exercise | 188,060 | -- | -- | 27% 709.52K to 897.58K | |
| 13-Sep-24 4:50 PM View: | Fox Chrisitne Ann Chief Financial Officer | Mereo Biopharma Group Plc (MREO) | 11-Sep-24 | Option Exercise | 60,000 | -- | -- | 104% 57.57K to 117.57K | |
| 13-Sep-24 4:49 PM View: | Lewicki John A. Chief Scientific Officer | Mereo Biopharma Group Plc (MREO) | 11-Sep-24 | Option Exercise | 46,000 | -- | -- | 73% 62.98K to 108.97K | |
| 23-Aug-24 6:13 PM View: | Pakianathan Deepika Director | Mereo Biopharma Group Plc (MREO) | 22-Aug-24 | Option Exercise | 105,244 | $1.44 | $151,116.00 | 100% 0 to 105.24K | |
| 23-Aug-24 6:13 PM View: | Pakianathan Deepika Director | Mereo Biopharma Group Plc (MREO) | 22-Aug-24 | Option Sale | 105,244 | $4.43 | $466,210.00 | (100%) 105.24K to 0 | |
| 27-Jun-24 4:15 PM View: | Lewicki John A. Chief Scientific Officer | Mereo Biopharma Group Plc (MREO) | 26-Jun-24 | Market Sale | 16,808 | $3.39 | $57,032.90 | (21%) 79.78K to 62.98K | (5%) |
| 27-Jun-24 4:15 PM View: | Hughes-Wilson Alexandra See Remarks | Mereo Biopharma Group Plc (MREO) | 26-Jun-24 | Market Sale | 22,968 | $3.39 | $77,935.00 | (40%) 57.52K to 34.55K | (5%) |
| 27-Jun-24 4:15 PM View: | Sermon Charles General Counsel | Mereo Biopharma Group Plc (MREO) | 26-Jun-24 | Market Sale | 32,187 | $3.39 | $109,217.00 | (15%) 216.57K to 184.39K | (5%) |
| 27-Jun-24 4:15 PM View: | Pollard-Knight Denise Chief Executive Officer Director | Mereo Biopharma Group Plc (MREO) | 26-Jun-24 | Market Sale | 92,273 | $3.39 | $313,101.00 | (12%) 801.79K to 709.52K | (5%) |
| 27-Jun-24 4:15 PM View: | Fox Chrisitne Ann Chief Financial Officer | Mereo Biopharma Group Plc (MREO) | 26-Jun-24 | Market Sale | 29,439 | $3.39 | $99,892.40 | (34%) 87.01K to 57.57K | (5%) |
| 27-Jun-24 4:15 PM View: | Lewicki John A. Chief Scientific Officer | Mereo Biopharma Group Plc (MREO) | 25-Jun-24 | Market Sale | 7,416 | $3.69 | $27,394.00 | (9%) 87.2K to 79.78K | 4% |
| 27-Jun-24 4:15 PM View: | Hughes-Wilson Alexandra See Remarks | Mereo Biopharma Group Plc (MREO) | 25-Jun-24 | Market Sale | 10,134 | $3.69 | $37,434.00 | (15%) 67.65K to 57.52K | 4% |
| 27-Jun-24 4:15 PM View: | Sermon Charles General Counsel | Mereo Biopharma Group Plc (MREO) | 25-Jun-24 | Market Sale | 14,202 | $3.69 | $52,460.80 | (6%) 230.78K to 216.57K | 4% |
| 27-Jun-24 4:15 PM View: | Pollard-Knight Denise Chief Executive Officer Director | Mereo Biopharma Group Plc (MREO) | 25-Jun-24 | Market Sale | 40,712 | $3.69 | $150,386.00 | (5%) 842.5K to 801.79K | 4% |
| 27-Jun-24 4:15 PM View: | Fox Chrisitne Ann Chief Financial Officer | Mereo Biopharma Group Plc (MREO) | 25-Jun-24 | Market Sale | 12,990 | $3.69 | $47,983.80 | (13%) 100.0K to 87.01K | 4% |
| 25-Jun-24 6:14 PM View: | Sermon Charles General Counsel | Mereo Biopharma Group Plc (MREO) | 21-Jun-24 | Option Exercise | 98,400 | -- | -- | 74% 132.38K to 230.78K | |
| 25-Jun-24 6:15 PM View: | Pollard-Knight Denise Chief Executive Officer Director | Mereo Biopharma Group Plc (MREO) | 21-Jun-24 | Option Exercise | 282,090 | -- | -- | 50% 560.41K to 842.5K | |
| 25-Jun-24 6:13 PM View: | Fox Chrisitne Ann Chief Financial Officer | Mereo Biopharma Group Plc (MREO) | 21-Jun-24 | Option Exercise | 90,000 | -- | -- | 900% 10.0K to 100.0K | |
| 25-Jun-24 6:13 PM View: | Hughes-Wilson Alexandra See Remarks | Mereo Biopharma Group Plc (MREO) | 21-Jun-24 | Option Exercise | 60,000 | -- | -- | 784% 7.65K to 67.65K | |
| 25-Jun-24 6:21 PM View: | Lewicki John A. Chief Scientific Officer | Mereo Biopharma Group Plc (MREO) | 21-Jun-24 | Option Exercise | 69,000 | -- | -- | 379% 18.2K to 87.2K | |
| 17-Jun-24 4:15 PM View: | Bender Jeremy Director | Mereo Biopharma Group Plc (MREO) | 17-Jun-24 | Grant | 12,550 | $3.99 | $50,074.50 | 100% 0 to 12.55K | |
| 17-Jun-24 4:15 PM View: | Wyzga Michael S Director | Mereo Biopharma Group Plc (MREO) | 17-Jun-24 | Grant | 25,050 | $3.99 | $99,949.50 | 100% 0 to 25.05K | |
| 23-May-24 10:00 PM View: | Hughes-Wilson Alexandra See Remarks | Mereo Biopharma Group Plc (MREO) | 22-May-24 | Option Exercise | 168,333 | $1.23 | $206,416.00 | 2200% 7.65K to 175.98K | |
| 23-May-24 10:00 PM View: | Hughes-Wilson Alexandra See Remarks | Mereo Biopharma Group Plc (MREO) | 22-May-24 | Payment of Exercise | 67,901 | $1.26 | $85,343.40 | (39%) 175.98K to 108.08K | |
| 23-May-24 10:00 PM View: | Hughes-Wilson Alexandra See Remarks | Mereo Biopharma Group Plc (MREO) | 22-May-24 | Option Sale | 100,432 | $2.97 | $297,788.00 | (93%) 108.08K to 7.65K |
